Stages and Diagnosis

Using the unique capabilities of the Allison Institute's immunotherapy platform, researchers discovered an immune signature linked with prolonged overall survival, which has the potential to help physicians identify who would be most likely to benefit from this combination.

Developed to calculate individual risk estimates of prostate cancer-specific mortality, the AI-powered platform marks the first externally developed prostate digital pathology algorithm embedded for clinical use within the Tempus diagnostics ecosystem.

This presentation reviews the current pathway for diagnosing prostate cancer and examines evidence supporting a newer, faster diagnostic approach. It also highlights outcomes of ablative therapies, including irreversible electroporation (IRE) and stereotactic ablative radiotherapy (SABR), and presents results from 5,000 transperineal prostate biopsies performed at North York General Hospital (presented by Barbod Azimikhiabani and Veselina Stefanova).

Dr. Andrew J. Evans (January, 2023) delivers a presentation regarding Gleason scores and pathology reports.

Learn about how the grade of a prostate tumour is assessed and what the Gleason score means.

What does the stage of a prostate tumour mean, and how is it determined? Find out about how the TNM staging system is used. *Published February 2021

This resource goes over the different types of biopsies for prostate cancer as well as complementary tests (Complete blood count, blood chemistry tests, bone scan, CT scan, MRI)

This resource covers the Gleason grade, Gleason score, the clinical stages and possible areas of metastasis, the risks of your cancer spreading and the types of prostate cancers.

Doctors use Prostate MRI to evaluate the extent of prostate cancer and determine whether it has spread. They may also use it to help diagnose infection, conditions you were born with, or an enlarged prostate. Some exams may use an endorectal coil, a thin wire covered with a latex balloon.